基于体内外成分关联法运用UPLC/MS-IT-TOF技术探讨彝族“黄药”抗非小细胞肺癌活性成分群的研究

肺癌恶性程度高、危害大，临床 缺乏理想药物。肺癌在彝医中属于"凶顽重症"，是彝医学的优势病种。"黄药"乃彝医学治疗肺癌的特色药物，在前期课题的基础上，已经确证黄药疗效，也发现了活性单体，但无法确定发挥作用的活性成分群。本项目以活性成分群理论为指导，利用代谢组学优势，采用成熟的体内外成分组关联分析策略，运用UFLC技术分析原药样品与给药组血清样本及代谢物样本间的成分差别，确定潜在的活性组分及代谢物，再利用HPLC-IT-TOF/MS联用技术，分析"黄药"抗肺癌活性成分群及其代谢物，通过高质量精度、高灵敏度的质谱数据，通过已知的"黄药"成分标准品比对、相同母核骨架对照解析、数据库搜索及分子离子化特征、分子特征裂解碎片解析等手段鉴定活性成分群中单体成分结构，最终得到"黄药"抗肺癌活性成分群，并有望得到结构新颖的单体，为彝族药物"黄药"现代化提供关键技术，有一定的示范性和科学价值。

The incidence and mortality of lung cancer are at the head of all cancer diseases, whose incidence and morility are 49.6/100000 and 30.3/100000 each in China. Lung cancer belongs to "XiongWangZhongZheng" theory system of YI medicine.HUANGYAO is a very effective medicine treating lung cancer in YI minority. Some studies suggested the anti-tumor activities of HUANGYAO, though the activity components were not definited. Based on the previous studies, the associated components analysis between origin and metabolites is used to find the activity componets group by comparing the orgin components group and the metabolites group. Then, ultra-flow liquid chromatography/ion trap-time-of-flight mass (UFLC/MS-IT-TOF) will be used to identify the structures of the activity components group. Depend on the UFLC/MS-IT-TOF, we can get high accuracy and high sensitivity mass data of the activity component group. By some methods such as standard substance comparison, comparing analysis of parent skeletons, searching from the database by formula,et al. to identify the structures of the single compounds in the activity components and metabolits. Our studies will provid experimental data and proof to the clinical use of HUANGYAO.